07:59 AM EST, 12/03/2024 (MT Newswires) -- Roivant Sciences ( ROIV ) said Tuesday its Kinevant Sciences unit's phase 2 Resolve-Lung trial for namilumab in chronic active pulmonary sarcoidosis failed to meet its primary and secondary endpoints.

Namilumab failed to meet the primary endpoint, showing no treatment benefit over placebo in reducing Rescue Events during the double-blind period. Secondary endpoints, including changes in lung function, corticosteroid tapering success, also did not demonstrate efficacy, it added.

Despite a safety profile consistent with earlier studies, Kinevant will discontinue namilumab's development for sarcoidosis.